Company intelligence / Profile preview

Forty 1° North

West Lafayette, Indiana, United Statesforty1north.com ↗

Ownership: Private
Development stage: Other

Overview

Forty 1° North is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for autoimmune and inflammatory diseases. The company's primary research centers on GPR183 (also known as EBI2), a G protein-coupled receptor that plays a critical role in the migration and activation of immune cells. By modulating GPR183, Forty 1° North aims to provide new treatment options for conditions such as inflammatory bowel disease and multiple sclerosis. The company leverages deep expertise in GPCR pharmacology to advance its pipeline of selective antagonists.

Therapeutic areas: ImmunologyNeurologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Forty 1° North.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forty 1° North.

Explore the full profile